IPX066 245 (Rytary carbidopa 61.25 mg / levodopa 245 mg)
Generic Name: carbidopa/levodopa
Pill imprint IPX066 245 has been identified as Rytary carbidopa 61.25 mg / levodopa 245 mg.
Rytary is used in the treatment of parkinson's disease and belongs to the drug class dopaminergic antiparkinsonism agents. Risk cannot be ruled out during pregnancy. Rytary carbidopa 61.25 mg / levodopa 245 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Generic Name:
- carbidopa/levodopa
- Imprint:
- IPX066 245
- Strength:
- carbidopa 61.25 mg / levodopa 245 mg
- Color:
- Blue
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Dopaminergic antiparkinsonism agents
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Impax Laboratories, Inc.
More about Rytary (carbidopa / levodopa)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 8 Reviews – Add your own review/rating
- Drug class: dopaminergic antiparkinsonism agents
Consumer resources
Other brands: Sinemet, Sinemet CR, Parcopa, Duopa
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
